Фибриновый клей в хирургической практике

Фибриновый клей (ФК) в хирургической практике применяется достаточно давно и является одним из инструментов для достижения гемостаза и профилактики периоперационного кровотечения. Выбор ФК при различных хирургических стратегиях влияет на клинический результат. Многочисленные исследования биологических и синтетических клеевых композиций показывают, что все еще имеется ограниченное количество данных о том, как тонкие различия в рецептурах фибриновых герметиков связаны с их клинической эффективностью и безопасностью. В этом обзоре мы попытались обобщить сведения по биологическим адгезивам — ФК, проследить историю внедрения в хирургическую практику ФК, осветить механизмы гелеобразования и адгезии, определяющие герметизирующие функции, изменение рецептуры составляющих клеевых композиций, а также проследить причины, побуждающие исследователей к поиску новых решений. Рассмотрены альтернативные технологии производства ФК, их преимущества и недостатки с учетом особенностей хирургического применения

1. Шатохина Н.А., Жуков С.В., Морозов А.М., Мноян А.Х., Муравлянцева М.М., Рыжова Т.С., Беляк М.А. О проблеме применения гемостатических средств в хирургической практике. Современные проблемы науки и образования. 2022;1:83–93. DOI: 10.17513/spno.31488

2. Демина Н.Б., Чернова Л.В., Козлова Ж.М. Применение клеевых композиций в хирургии. Хирургия. Журнал им. Н.И. Пирогова. 2019;(3):129–134. (In Russian)]. DOI: 10.17116/hirurgia2019031129

3. Ghosh S., Gayen P., Jan S., Kishore A.V., Kumar V., Mallick A.M., Mukherjee A., Nandi S.K., Sinha Roy R. Bioinspired Non-Immunogenic Multifunctional Sealant for Efficient Blood Clotting and Suture-Free Wound Closure. ACS Biomater. Sci. Eng. 2020;6(11):6378–6393. DOI: 10.1021/acsbiomaterials.0c01254

4. Burnouf T., Goubran H.A., Chen T.M., Ou K.L., El-Ekiaby M., Radosevic M. Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev. 2013; 27(2):77–89. DOI: 10.1016/j.blre.2013.02.001

5. Burnouf T., Su. C.Y., Radosevich M., Goubran H. and El-Ekiaby M. Blood-derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. ISBT Science Series. 2009; 4:136–142. DOI: 10.1111/j.1751-2824.2009.01222.x

6. Buchta C., Hedrich H.C., Macher M., Höcker P., Redl H. Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel. Biomaterials. 2005;26(31):6233–41. DOI: 10.1016/j.biomaterials.2005.04.014

7. Bergel S. Ueber Wirkungen des Fibrins. Dtsch Med Wochenschr.1909;35(15):663–665. DOI: 10.1055/s-0029-1201395

8. Grey E.G. Fibrin as a hemostatic in cerebral surgery. Surg. Gynecol. Obstet. 1915;21:452–454.

9. Harvey S.C. The use of fibrin paper and forms in cerebral surgery. Boston Medical and Surgical J. 1916;174:658–659.

10. Cronkite E.P., Lozner E.L., Deaver J.M. Use of thrombin and fibrinogen in skin grafting: preliminary report. JAMA. 1944;124(14):976– 978. DOI: 10.1001/jama.1944.02850140022006

11. Tidrick R.T., Warner E.D. Fibrin fixation of skin transplants. Surgery. 1944;15:90–95. DOI: 10.5555/uri:pii:S0039606044900528

12. Cohn E.J., Strong L.E. Hughes W.L., Mulford D.J., Ashworth J.N., Melin M., Taylor H.L. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fl uids. J. Am. Chem. Soc. 1946;68(3):459–475. DOI: 10.1021/ja01207a034

13. Matras H. The use of fibrin sealant in oral and maxillofacial surgery. J. Oral Maxillofac. Surg. 1982;40(10):617–22. DOI: 10.1016/0278-2391(82)90108-2

14. Gugerell A., Schossleitner K., Wolbank S., Nürnberger S., Redl H., Gulle H., Goppelt A., Bittner M., Pasteiner W. High thrombin concen trations in fibrin sealants induce apoptosis in human keratinocytes. J. Biomed. Mater. Res. A. 2012;100(5):1239–47. DOI: 10.1002/jbm.a.34007

15. Cheng C.M., Meyer-Massetti C., Kayser S.R. A review of three stand-alone topical thrombins for surgical hemostasis. Clin. Ther. 2009;31(1):32–41. DOI: 10.1016/j.clinthera.2009.01.005

16. Bhandari M., Ofosu F.A., Mackman N., Jackson C., Doria C., Humphries J.E. et al. Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus. Clin. Appl. Thromb. Hemost. 2011;17(1):39–45. DOI: 10.1177/1076029610385674

17. Paulmier P. The main problem with biological products of animal origin. Biologicals. 2000;28(1):55. DOI: 10.1006/biol.1999.0237

18. Spotnitz W. Fibrin sealant patches: powerful and easy-to-use hemostats. Open Access Surgery. 2014;7:71–79. DOI: 10.2147/OAS. S41516.

19. Reiner A.P. Fibrin glue increasingly popular for topical surgical hemostasis. Laboratory Medicine. 1999;30(3):189–193. DOI: 10.1093/labmed/30.3.189 .

20. Pavie A., Szefner J., Leger P., Gandjbakhch I. Preventing, minimizing, and managing postoperative bleeding. Ann. Thorac. Surg. 1999;68(2):705–10. DOI: 10.1016/s0003-4975(99)00628-1

21. Scognamiglio F., Travan A., Rustighi I., Tarchi P., Palmisano S., Marsich E. et al. Adhesive and sealant interfaces for general surgery applications. J. Biomed. Mater. Res. B Appl. Biomater. 2016;104(3):626–39. DOI: 10.1002/jbm.b.33409

22. Pipan C.M., Glasheen W.P., Matthew T.L., Gonias S.L., Hwang L.J., Jane J.A., Spotnitz W.D. Eff ects of antifibrinolytic agents on the life span of fibrin sealant. J. Surg. Res. 1992;53(4):402–7. DOI: 10.1016/0022-4804(92)90068-b

23. Smith J.D., Chen A., Ernst L.A., Waggoner A.S., Campbell P.G. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels. Bioconjug. Chem. 2007;18(3):695– 701. DOI: 10.1021/bc060265o

24. Beudert M., Gutmann M., Lühmann T., Meinel L. Fibrin sealants: challenges and solutions. ACS Biomater. Sci. Eng. 2022;8(6):2220– 2231.

25. Tredree R., Beierlein W., Debrix I., Eisert A., Goff redo F., de Salazar E.G. et al. Evaluating the diff erences between fibrin sealants: recommendations from an international advisory panel of hospital pharmacists. Eur. J. Hosp. Pharm. 2006;12(1):3–9.

26. Lorentz K.M., Kontos S., Frey P., Hubbell J.A. Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials. 2011;32(2):430–438. DOI: 10.1016/j.biomaterials.2010.08.109

27. Shaff rey C.I., Spotnitz W.D., Shaff rey M.E., Jane J.A. Neurosurgical applications of fibrin glue: augmentation of dural closure in 134 patients. Neurosurgery. 1990;26(2):207–10.

28. Nakamura H., Matsuyama Y., Yoshihara H et al. The eff ect of autologous fibrin tissue adhesive on postoperative cerebrospinal fl uid leak in spinal cord surgery: a randomized controlled trial. Spine. 2005;30(13):E347–51. DOI: 10.1097/01.brs.0000167820.54413.8e

29. Lassen M.R., Solgaard S., Kjersgaard AG., Olsen C., Lind B., Mittet K., Ganes H.C. A pilot study of the eff ects of Vivostat patient-derived fibrin sealant in reducing blood loss in primary hip arthroplasty. Clin. Appl. Thromb. Hemost. 2006;12(3):352–7. DOI: 10.1177/1076029606291406

30. Fischer C.P., Wood C.G., Shen J., Batiller J., Hart J.C., Patel B., Albala D.M. A randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat. Clin. Appl. Thromb. Hemost. 2011;17(6):572-7. DOI: 10.1177/1076029611404212

31. Guterl CC., Torre O.M., Purmessur D., Dave K., Likhitpanichkul M., Hecht A.C., Nicoll S.B, Iatridis J.C. Characterization of mechanics and cytocompatibility of fibrin-genipin annulus fibrosus sealant with the addition of cell adhesion molecules. Tissue Eng. Part A. 2014;20(17–18):2536–45. DOI: 10.1089/ten.TEA.2012.0714

32. Лоенко Ю.Н., Артюков А.А., Лямкин Г.П., Глазкова В.Е., Руцкова Т.А. Лектины и агглютинины морских водорослей. Раст. ресурсы. 1990:26(2):263–274.

33. Scognamiglio F., Travan A., Rustighi I., Tarchi P., Palmisano S., Marsich E., Borgogna M., Donati I., de Manzini N., Paoletti S. Adhesive and sealant interfaces for general surgery applications. J. Biomed. Mater. Res. B Appl. Biomater. 2016;104(3):626–39. DOI: 10.1002/jbm.b.33409

34. Deslys J., Comoy E., Hawkins S. et al. Screening slaughtered cattle for BSE. Nature. 2001;409(25):476–478.

35. Schwarz T.F. Ubertragung von parvovirus B19 durch blut und blutkomponenten (German). [Transmission of parvovirus B19 by blood and blood components]. Infusionsther Transfusionsmed. 1994;21(1):27–31.

36. Ham S.W., Lew W.K., Weaver F.A. Thrombin use in surgery: an evidence-based review of its clinical use. J Blood Med. 2010;1:135-42. DOI: 10.2147/JBM.S6622. Epub 2010 Jul 22. Retraction in: J. Blood Med. 2022;13:165-166.

37. Lopez M.J., Yandrapalli S. Thrombin. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. URL: https://www.ncbi.nlm.nih.gov/books/NBK557836.

38. Wilson S.M., Pell P. Donegan E.A. HIV-1 Transmission Following the Use of Cryoprecipitate Fibrinogen as Gel/Adhesive. Transfusion. 1991;31:51S.

39. Bänninger H., Hardegger T., Tobler A., Barth A., Schüpbach P., Reinhart W., Lämmle B., Furlan M. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br. J. Haematol. 1993;85(3):528–32. DOI: 10.1111/j.1365-2141.1993.tb03343.x

40. Berruyer M., Amiral J., Ffrench P., Belleville J., Bastien O., Clerc J. et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J. Thorac. Cardiovasc. Surg. 1993;105(5):892–7.

41. Lundblad R.L., Bradshaw R.A., Gabriel D., Ortel T.L., Lawson J., Mann K.G. A review of the therapeutic uses of thrombin. Thromb. Haemost. 2004;91(5):851–60. DOI: 10.1160/TH03-12-0792

42. Ness P., Creer M., Rodgers G.M., Naoum J.J., Renkens K., Voils S.A., Alexander W.A. Recognition, evaluation and treatment of acquired coagulopathy consensus (RETACC) panel. Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety. Patient Saf. Surg. 2009;3(1):8. DOI: 10.1186/1754-9493-3-8

43. Zehnder J.L., Leung L.L. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990;76(10):2011–6.

44. Bishop P.D., Lewis K.B., Schultz J., Walker K.M. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin. Thromb. Hemost. 2006;32(1):86–97. DOI: 10.1055/s-2006-939558

45. Croxtall J.D., Scott L.J. Recombinant human thrombin: in surgical hemostasis. BioDrugs. 2009;23(5):333–8. DOI: 10.2165/11202650-000000000-00000

46. Han B., Woodell-May J., Ponticiello M., Yang Z., Nimni M. The eff ect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity. J. Bone Joint Surg. Am. 2009;91(6):1459–70. DOI: 10.2106/JBJS.H.00246

47. LeBlanc H., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Diff er. 2003:10:66–75. DOI: 10.1038/sj.cdd.4401187

48. Reichsöllner R., Heher P., Hartmann J. A comparative high-resolution physicochemical analysis of commercially available fibrin sealants: Impact of sealant osmolality on biological performance. 2022. Journal of Biomedical Materials Research. 2022;111(4):488– 501DOI:10.1002/jbm.a.37466.

49. Bell W.R. Jr. Defibrinogenating enzymes. Drugs. 1997;54(3):18–30; discussion 30–1. DOI: 10.2165/00003495-199700543-00005

50. Velada J.L., Hollingsbee D.A., Menzies A.R., Cornwell R., Dodd R.A. Reproducibility of the mechanical properties of Vivostat system patient-derived fibrin sealant. Biomaterials. 2002;23(10):2249–54. DOI: 10.1016/s0142-9612(01)00359-3

51. Bordon K.C.F., Cologna C.T., Fornari-Baldo E.C., Pinheiro-Júnior E.L., Cerni F.A., Amorim F.G. et al. From animal poisons and venoms to medicines: achievements, challenges and perspectives in drug discovery. Front Pharmacol. 2020 24;11:1132. DOI: 10.3389/fphar.2020.01132

52. Vu T.T., Staff ord A.R., Leslie B.A., Kim P.Y., Fredenburgh J.C., Weitz J.I. Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. J. Biol. Chem. 2013;288(23):16862–16871. DOI: 10.1074/jbc.M113.464750

53. Mosesson M.W., Siebenlist K.R., Meh D.A. The structure and biological features of fibrinogen and fibrin. Ann. N.-Y. Acad. Sci. 2001;936:11–30. DOI: 10.1111/j.1749-6632.2001.tb03491.x

54. Kjaergard H.K., Fairbrother J.E. Controlled clinical studies of fibrin sealant in cardiothoracic surgery — a review. Eur. J. Cardiothorac. Surg. 1996;10(9):727–33. DOI: 10.1016/s1010-7940(96)80332-0

55. Rousou J., Levitsky S., Gonzalez-Lavin L., Cosgrove D., Magilligan D., Weldon C. et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. J. Thorac. Cardiovasc. Surg. 1989;97(2):194–203.

56. Berg P.L., Barina W., Born P. Endoscopic injection of fibrin glue versus polidocanol in peptic ulcer hemorrhage: a pilot study. Endoscopy. 1994;26(6):528–30. DOI: 10.1055/s-2007-1009028

57. Fibrin Sealants Market, By Product Type (Liquid Fibrin Sealants and Patch-based Fibrin Sealants), By Application (General Surgery, Cardiovascular Surgery, Orthopedic Surgery, Neurosurgery, and Others), and By Region Forecast to 2032. Pharma and Healthcare — Fibrin Sealants Market. URL: https://www.reportsanddata.com/report-detail/fibrin-sealants-market

58. Shaff rey C.I., Spotnitz W.D., Shaff rey M.E., Jane J.A. Neurosurgical applications of fibrin glue: augmentation of dural closure in 134 patients. Neurosurgery. 1990;26(2):207–10.

59. Arnautovic K.I., Kovacevic M. CSF-Related Complications After Intradural Spinal Tumor Surgery: Utility of an Autologous Fat Graft. Medical Archives (Sarajevo, Bosnia and Herzegovina). 2016;70(6):460–465. DOI: 10.5455/medarh.2016.70.460-465. PMID: 28210022

60. Lars Poulsgaard, Anette Mørck, Niels Erik Holm. A Safety Study of the Use of Vivostat® Patient-Derived Fibrin Sealant Containing Tranexamic Acid in Neurosurgery. Skull Base Surgery. 2007;17:A023. DOI: 10.1055/s-2007-981728

61. Koea J., Baldwin P., Shen J., Patel B., Batiller J., Arnaud A. et al. Safety and hemostatic eff ectiveness of the fibrin pad for severe soft-tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic (non-cardiac) surgery: a randomized, controlled, superiority trial. World J. Surg. 2015;39(11):2663–9. DOI: 10.1007/s00268-015-3106-5

62. Graziano F., Certo F., Basile L., Maugeri R., Grasso G., Meccio F., Ganau M., Iacopino D.G. Autologous fibrin sealant (Vivostat(®)) in the neurosurgical practice: Part I: Intracranial surgical procedure. Surg. Neurol. Int. 2015;6:77. DOI: 10.4103/2152-7806.156871

63. Fukumoto T., Matsushima Y., Tomita S., Inaba Y. The use of fibrin glue in neurosurgical operations. No Shinkei Geka. 1985;13(4): 367–73.

64. Graziano F., Maugeri R., Basile L., Meccio F., Iacopino D.G. Aulogous fibrin sealant (Vivostat(®)) in the neurosurgical practice: Part II: Vertebro-spinal procedures. Surg. Neurol. Int. 2016;7(3):S77–82. DOI: 10.4103/2152-7806.174894

65. Karmaker A., Ahmed Sh. Fibrin glue sources, characteristics and applications. in: adhesives in biomedical applications. book editor(s): K.L. Mittal, S. Neogi. 2023. DOI: 10.1002/9781394209897.ch5

66. Corral M., Ferko N., Hogan A., Hollmann S.S. A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding. DOI: 10.2147/CEOR.S112762

67. Davidson B.R., Burnett S., Javed M.S., Seifalian A., Moore D., Doctor N. Experimental study of a novel fibrin sealant for achieving haemostasis following partial hepatectomy. Br. J. Surg. 2000;87(6):790–5. DOI: 10.1046/j.1365-2168.2000.01427.x

68. Harmon A.M., Kong W., Buensuceso C.S., Gorman A.J., Muench T.R. Eff ects of fibrin pad hemostat on the wound healing process in vivo and in vitro. Biomaterials. 2011;32(36):9594–601. DOI: 10.1016/j.biomaterials.2011.09.019

69. Caiado F., Carvalho T., Silva F., Castro C., Clode N., Dye J.F., Dias S. The role of fibrin E on the modulation of endothelial progenitors adhesion, diff erentiation and angiogenic growth factor production and the promotion of wound healing. Biomaterials. 2011;32(29):7096– 105. DOI: 10.1016/j.biomaterials.2011.06.022

70. Corral M., Ferko N., Hollmann S., Hogan A., Jamous N., Batiller J. Clinician reported ease of use for a novel fibrin sealant patch for hemostasis: results from four randomized controlled trials. Curr. Med. Res. Opin. 2016;32(2):367–75. DOI: 10.1185/03007995.2015.1128405

71. Fischer C.P., Bochicchio G., Shen J., Patel B., Batiller J., Hart J.C. A prospective, randomized, controlled trial of the efficacy and safety of fibrin pad as an adjunct to control soft tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic surgery. J. Am. Coll. Surg. 2013;217(3):385–93. DOI: 10.1016/j.jamcollsurg.2013.02.036

72. Koea J.B., Batiller J., Patel B., Shen J., Hammond J., Hart J., Fischer C., Garden O.J. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB (Oxford). 2013;15(1):61–70. DOI: 10.1111/j.1477-2574.2012.00583.x. –

73. Fischer C.P., Wood C.G., Shen J., Batiller J., Hart J.C., Patel B., Albala D.M. A randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat. Clin. Appl. Thromb. Hemost. 2011;17(6):572– 7. DOI: 10.1177/1076029611404212

74. Giannini S., Buda R., Cavallo M., Ruffilli A., Cenacchi A., Cavallo C., Vannini F. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bonemarrow-derived cells transplantation. Injury. 2010;41(11):1196–203. DOI: 10.1016/j.injury.2010.09.028

75. Fontein D., Burger M., Mannil L., Giovanoli P., Plock J. Evaluation of platelet-rich fibrin in deep dermal burn: a case study. Congress of Swiss Plastic Surgery. September 2017. St. Moritz, Schwitzerland.

76. Knee surgeons at London Bridge Hospital get stuck into the use of Biological glues. London Bridge Hospital. Health Matters. 2016;18:11.